Elevai Labs, Inc. Common Stock (ELAB) - Total Liabilities
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) has total liabilities worth $5.03 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Elevai Labs, Inc. Common Stock - Total Liabilities Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Elevai Labs, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Elevai Labs, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Elevai Labs, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Schroder Real Estate Investment Trust Ltd
LSE:SREI
|
UK | GBX199.08 Million |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
UK | GBX4.06 Million |
|
iMetal Resources Inc
V:IMR
|
Canada | CA$933.29K |
|
Infinity Mining Ltd
AU:IMI
|
Australia | AU$392.72K |
|
Rocky Mountain Liquor Inc
V:RUM
|
Canada | CA$12.35 Million |
|
Tlou Energy Ltd
AU:TOU
|
Australia | AU$23.72 Million |
|
Unity Biotechnology Inc
NASDAQ:UBX
|
USA | $30.55 Million |
|
Hansa Trust
LSE:HAN
|
UK | GBX1.42 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Elevai Labs, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Elevai Labs, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elevai Labs, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of Elevai Labs, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.03 Million | +115.59% |
| 2024-12-31 | $2.33 Million | +71.23% |
| 2023-12-31 | $1.36 Million | +79.12% |
| 2022-12-31 | $760.87K | +252.87% |
| 2021-12-31 | $215.62K | +430.94% |
| 2020-12-31 | $40.61K | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more